Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713308 | 0.86 | LMNA (0.52) | CA12CA1CA2CA4CA6 | |
| SCHEMBL978445 | 0.84 | MAPT (0.46) | CNR2MAPK1 | |
| SCHEMBL2714328 | 0.83 | TSHR (0.51) | HTTTSHRMRGPRX4LMNAMAPK1 | |
| SCHEMBL27931887 | 0.81 | MEN1 (0.49) | TSHRMAPK1RAB9A | |
| SCHEMBL976853 | 0.81 | XDH (0.48) | HCAR2NAPRT | |
| SCHEMBL7652014 | 0.80 | PTGS2 (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL15968157 | 0.80 | CA1 (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL29612133 | 0.80 | PTGS2 (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8768358 | 0.80 | CA12 (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL16387002 | 0.80 | CA12 (0.53) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-20250215016-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai SIMR Biotechnology Co., Ltd (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506348-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simrd Biotechnology Co., Ltd (CN) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024157014-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-116854680-A | Isoxazole-heterocycle derivatives, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023185704-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | 上海赛默罗生物科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| WO-2008057129-A1 | MULTI-SUBSTITUTED PYRIDYL SULFOXIMINES AND THEIR USE AS INSECTICIDES | DOW AGROSCIENCES LLC (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057129-A1 | MULTI-SUBSTITUTED PYRIDYL SULFOXIMINES AND THEIR USE AS INSECTICIDES | DOW AGROSCIENCES LLC (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | CORTEVA AGRISCIENCE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | CORTEVA AGRISCIENCE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | CORTEVA AGRISCIENCE LLC | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | CA12 4572/4885CA1 3705/4885CA2 2723/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | CA12 2844/4885CA1 1239/4885CA2 285/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | CA12 1892/4885CA1 2996/4885CA2 1861/4885 |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | PIR, PNPO, PRDX4 | CA12 4709/4885CA1 4753/4885CA2 4441/4885 |
| US-20250215016-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | GABRA5, GABRA1, CYP3A5 | CA12 3515/4885CA1 2548/4885CA2 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.